M. D. Anderson Cancer Center - News Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

MD Anderson Cancer Center Board of Visitors welcomes 14 new members
The University of Texas MD Anderson Cancer Center Board of Visitors, an appointed board of volunteers charged with advancing MD Anderson's goal to end cancer, will welcome 14 new members at its annual meeting Oct. 28-29 in Houston. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 9, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson, Theraclone Sciences form OncoResponse
OncoResponse, an immuno-oncology antibody discovery company, has been launched jointly by The University of Texas MD Anderson Cancer Center and Theraclone Sciences. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 6, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson's Allison wins American Cancer Society medal of honor
A career-long fascination with discovering the ins and outs of T cells, our immune system's tailor-made destroyers of infections and dysfunctional cells, has earned Jim Allison, Ph.D., the American Cancer Society's 2015 Medal of Honor for Basic Research.  (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 2, 2015 Category: Cancer & Oncology Source Type: news

Study shows new 'driver' to assess cancer patient survival and drug sensitivity
Cancer specialists have long looked at genetic mutations and DNA copy changes to help predict patient survival and drug sensitivity. A study led by The University of Texas MD Anderson Cancer Center has opened up yet another avenue for understanding the biological reasons why some people live longer or respond better to treatment - RNA editing events. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 1, 2015 Category: Cancer & Oncology Source Type: news

Everolimus provides new hope for neuroendocrine tumours
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors (NET) of the lung and gastrointestinal tract. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 26, 2015 Category: Cancer & Oncology Source Type: news

Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited. Researchers at The University of Texas MD Anderson Cancer Center demonstrated a median overall survival benefit of 25 months with nivolumab, a Food and Drug Administration (FDA)-approved immunotherapy agent, compared with 19.6 months for everolimus, a current standard of care for patients with metastatic kidney cancer. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 25, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson study identifies leukemia tumor suppressor
A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 24, 2015 Category: Cancer & Oncology Source Type: news

A Conversation With a Living Legend returns to San Antonio to honor Emmitt Smith
The University of Texas MD Anderson Cancer Center heads to San Antonio Oct. 13 for the sixth annual A Conversation With a Living Legend honoring Pro Football Hall of Fame member and "Dancing with the Stars" champion Emmitt Smith. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 22, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson, Cayman Chemical, and Fannin Innovation Studio form therapeutics company
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio have formed ACF Pharmaceuticals, LLC. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 15, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson immunologist Jim Allison wins Lasker-DeBakey Award
For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 8, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson and Cellectis announce pre-clinical and clinical alliance in cancer immunotherapy
Cellectis, the gene editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, and The University of Texas MD Anderson Cancer Center have entered into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 3, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson brings Making Cancer History® seminar to Atlanta
The University of Texas MD Anderson Cancer Center heads to Atlanta for a Making Cancer History® seminar, 8:30-10 a.m. Friday, Sept. 25 at the Intercontinental Buckhead Atlanta Hotel, 3315 Peachtree Rd. NE. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 3, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson to honor Houstonians for their efforts to end cancer
The University of Texas MD Anderson Cancer Center will host a celebratory reception honoring hundreds of Houston-area donors on Wednesday, Sept. 9 from 6 to 8 p.m. at the River Oaks Country Club, 1600 River Oaks Blvd. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 2, 2015 Category: Cancer & Oncology Source Type: news

Michelle Barton receives Rogers Award for Excellence in Education
Michelle Barton, Ph.D., professor, Epigenetics and Molecular Carcinogenesis at MD Anderson Cancer Center, is the 2015 recipient of the Julie and Ben Rogers Award for Excellence in Education. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 1, 2015 Category: Cancer & Oncology Source Type: news

Internationally recognized health care leader to direct MD Anderson Moon Shots Program prevention efforts
The University of Texas MD Anderson Cancer Center has appointed former U.S. Public Health Service four-star Admiral Joxel Garcia, M.D. as the inaugural executive director of the cancer prevention and control platform, part of MD Anderson's Moon Shots Program. He joins MD Anderson on Aug. 31. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - August 26, 2015 Category: Cancer & Oncology Source Type: news